In our study, the most common gene alterations in the 66 primary pancreatic cancers were KRAS (96.9%), TP53 (81.2%), CDKN2A (35.9%), and SMAD4 (15.6%) (Figure 2A). This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.